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Summary Statins have been shown to reduce cardiovascular events across a broad spectrum
of patients at risk, irrespective of baseline LDL-cholesterol levels. In a meta-analysis of 14 statin
trials involving more than 90,000 participants, statin therapy reduced the 5-year incidence of
cardiovascular events by about 20% for each mmol/L of LDL-cholesterol reduction. The results
of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese
(MEGA) study suggest that the degree of reduction in Japanese subjects may be greater than this
for the same degree of LDL-cholesterol reduction. Given the success of statins in preventing
cardiovascular events, it is not surprising that they have been tested in a variety of related
conditions, three of which are discussed in this article.
Heart failure is characterized by inﬂammation, endothelial dysfunction and neurohumeral
activation, conditions that are ameliorated by statin therapy. The Controlled Rosuvastatin Multi-
national Trial in Heart Failure (CORONA) showed no signiﬁcant beneﬁt of rosuvastatin upon the
primary endpoint, cardiovascular death, myocardial infarction and stroke. However, subgroups
identiﬁed by the biomarkers plasma amino-terminal pro-brain natriuretic and C-reactive protein
showed a reduction in events.
Aortic stenosis and atherosclerosis share common risk factors, including hypertension and
hypercholesterolemia. Although non-randomized cohort studies have suggested that statins slow
the progression of aortic stenosis, this was not shown in either of the two randomized placebo-
controlled trials testing this hypothesis.
Similarly, Alzheimer’s disease shares many risk factors with atherosclerosis, and several obser-
vational studies have reported a lower risk of developing this condition in patients taking
statins. However, two recently completed clinical trials indicate that neither atorvastatin nor
simvastatin slow the progression of early Alzheimer’s disease.
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In conclusion, although statins are effective, established therapy for the prevention of vas-
cular events in patients at risk, they have as yet not proven to be successful for these newer
indications.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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ot of myalgias, creatinine kinase elevations, rhabdomyol-
sis, or withdrawal of therapy compared to placebo [11].
n clinical practice, the most serious adverse effects of
tatin treatment are myopathy or rhabdomyolysis; however,
hese complications are very uncommon and occur mainly
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n subjects taking gemﬁbrozil or drugs metabolized by the
ytochrome P450 3A4 [12]. The incidence of new onset dia-
etes was higher in patients taking rosuvastatin 20mg or
torvastatin 80mg compared to placebo in two clinical trials
8,9,13]. This complication is more common in patients with
igher fasting blood glucose levels at baseline or features of
he metabolic syndrome.
The efﬁcacy of a statin for reducing cardiovascular events
n a Japanese population was clearly demonstrated in the
anagement of Elevated Cholesterol in the Primary Preven-
ion Group of Adult Japanese (MEGA) study [14]. In fact,
he results of the MEGA trial suggest that the degree of
vent reduction in Japanese subjects is greater than that
een in non-Japanese populations for the same degree of
DL-cholesterol reduction. The long-term safety of statins
as been well documented in Japanese patients [15,16].
Given the success of statins in the prevention of cardio-
ascular events, it should not be surprising that they have
een tested in a variety of related conditions. By block-
ng the 3-hydroxy-3-methylglutaryl-coenzyme A reductase
nzyme, statins not only reduce blood cholesterol levels,
ut also prevent the synthesis of important isoprenoid inter-
ediates of the cholesterol pathway, ultimately inhibiting
he isoprenylation of the small GTP-binding proteins, Ras,
ac, and Rho [17]. These small proteins exert a wide variety
f different effects within the body, and thus statins have
any potential therapeutic beneﬁts that are unrelated to
holesterol lowering.
Three of the conditions where statins have been eval-
ated are heart failure, aortic stenosis, and Alzheimer’s
isease. In each case, animal data and observational studies
uggested that statins would improve outcomes; however,
he results of clinical trials have been disappointing, as out-
ined below.
tatins for the treatment of heart failure
he early statin trials were focused on LDL-cholesterol
owering as the mechanism of beneﬁt, and thus patients
ith heart failure were mostly excluded. However, heartReferences .................................................
Introduction
Statins are arguably the most successful class of drugs in
history. Originally discovered by Akiro Endo in the 1970s
and developed by Merck Research Laboratories [1], statins
ﬁrst became available in the United States of America
in 1987 as a treatment to lower low-density lipoprotein
(LDL)-cholesterol. In 1994, the ﬁrst randomized, placebo-
controlled clinical trial showing that a statin reduced
cardiovascular events was published [2]. A meta-analysis
of 14 statin trials involving more than 90,000 participants,
published in 2005, concluded that statin therapy reduced
the 5-year incidence of cardiovascular events by about
20% for each mmol/L of LDL-cholesterol reduction [3].
This reduction in events occurred irrespective of baseline
LDL-cholesterol level or of other baseline features of the
patients. With this strong evidence base from clinical trials,
global statin sales totaled $23 billion in 2006 [4].
Indications for statin therapy
A statin should be given to patients who are at moderate
or elevated risk for a cardiovascular event. This includes
all patients with established atherosclerosis irrespective of
baseline LDL-cholesterol level [5], and other groups such
as patients with diabetes [6] or hypertension plus other
risk factors [7]. Statins reduced the risk of cerebrovascular
and coronary events after an ischemic stroke or transient
ischemic attack [8], and have been shown to reduce events
in subjects with normal cholesterol levels, no evidence of
vascular disease, but elevated C-reactive protein levels [9].
In patients with stable coronary disease, aggressive LDL-
cholesterol lowering with a high dose has been shown to
reduce events more than less LDL-cholesterol lowering with
a low dose of statin [10].
Statins have proven to be remarkably safe. In clinical
trials covering 74,102 subjects, statin therapy was associ-
ated with a small excess risk of transaminase elevations, butailure is characterized by inﬂammation, endothelial dys-
unction, and neurohumoral activation, conditions that are
meliorated by statin therapy. In animal studies, statins
ave favorable effects on left ventricular remodeling after
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Table 1 Incidence of new onset heart failure (HF) or hospitalization for heart failure in selected major statin trials.
Trial Patients Drug Control HF: drug HF: control Hazard ratio (95% CI)
HPS [22] 20,536 Simvastatin 40mg Placebo 3.4% 3.9% 0.86 (0.75—1.00)
PROVE-IT [24] 4,162 Atorvastatin 80mg Pravastatin 40mg 1.6% 3.1% 0.55 (0.35—0.85)
TNT [23] 10,001 Atorvastatin 80mg Atorvastatin 10mg 2.4% 3.3% 0.74 (0.59—0.94)
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IDEAL [26] 8,888 Atorvastatin 80mg Simvast
myocardial infarction [18]. In clinical studies of patients
with non-ischemic cardiomyopathy, simvastatin and atorvas-
tatin have been shown to improve heart failure symptoms
and ejection fraction, and to lower plasma levels of proin-
ﬂammatory cytokines and natriuretic peptides compared to
placebo [19,20].
In several of the major randomized trials, statins have
exerted a favorable effect upon heart failure, as listed
in Table 1 [21—26]. In the Heart Protection Study, 20,536
patients at high-risk for a vascular event were random-
ized to simvastatin 40mg/day or placebo and were followed
for 5 years. Major vascular events were reduced by 24%
in the simvastatin group (95% conﬁdence interval 19—28%).
Hospitalization for heart failure was reduced by 14% (95%
conﬁdence interval 0—25%) [22] this study, N-terminal pro-
B-type natriuretic peptide levels were strongly predictive
of major vascular events, including heart failure hospital-
izations, and in patients with high baseline levels of this
biomarker for heart failure, simvastatin reduced vascular
risk, with no evidence of hazard [21].
In the Pravastatin or Atorvastatin Evaluation and Infec-
tion Trial (PROVE-IT), 4,162 patients were randomized to
atorvastatin 80mg/day or pravastatin 40mg/day after an
acute coronary syndrome, and were followed for 2 years.
The primary endpoint, (a composite of death, myocardial
infarction, documented unstable angina requiring hospi-
talization, stroke, and revascularization after 30 days),
occurred in 22.4% of atorvastatin and 26.3% of pravastatin-
treated patients (hazard ratio 0.84, 95% conﬁdence interval
0.74—0.95, p = 0.005). Treatment with atorvastatin signiﬁ-
cantly reduced the rate of hospitalization for heart failure
(1.6% versus 3.1%, hazard ratio 0.55, 95% conﬁdence inter-
val 0.35—0.85, p = 0.008) [23]. The risk of heart failure
hospitalization was higher with increasing levels of B-type
natriuretic peptide, and at these higher levels, atorvastatin
treatment signiﬁcantly reduced risk.
In the Treating to New Targets (TNT) trial, 10,001 patients
with stable coronary disease were randomized to 10mg
or 80mg/day of atorvastatin and were followed for 4.9
years. The primary endpoint, (a composite of cardiac death,
non-fatal myocardial infarction, and stroke), was reduced
from 10.9% to 8.7% in the 80mg group (hazard ratio 0.78,
95% conﬁdence interval 0.69—0.89, p < 0.001). Hospitaliza-
tion for heart failure, a prespeciﬁed secondary endpoint of
TNT, was reduced from 3.3% in the 10mg group to 2.4% in
the 80mg group (hazard ratio 0.74, 95% conﬁdence inter-
val 0.59—0.94, p = 0.012) [23]. The treatment effect of the
higher dose was more marked in patients with a history of
heart failure, 17.3% and 10.6% in the 10 and 80mg arms,
respectively (hazard ratio 0.59, 95% conﬁdence interval
0.40—0.88, p = 0.009).
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b20mg 3.7% 5.0% 0.72 (0.53—0.98)
20mg 2.2% 2.8% 0.80 (0.61—1.05)
In the Z phase of the A to Z trial, 4,497 acute coro-
ary syndrome patients were randomized to either placebo
or 4 months followed by simvastatin 20 or 40mg/day of
imvastatin, increasing to 80mg/day after 1 month [25].
fter a median follow-up of approximately 2 years, the pri-
ary endpoint was not signiﬁcantly reduced in the more
ggressively treated group; however, new onset heart fail-
re was reduced from 5.0% to 3.7% (hazard ratio 0.72, 95%
onﬁdence interval 0.53—0.98, p = 0.04). A trend toward a
eduction in heart failure hospitalizations was seen in the
ncremental Decrease in End Points through Aggressive Lipid
owering (IDEAL) trial (hazard ratio 0.80, 95% conﬁdence
nterval 0.61—1.05), a study where 8,888 patients with a his-
ory of myocardial infarction were randomized to 80mg/day
f atorvastatin or 20mg/day of simvastatin and were fol-
owed for 4.8 years [26].
All of the foregoing data suggest that a statin, or a
igh-dose compared to a low-dose statin, will reduce the
isk of hospitalizations for heart failure in patients with
oronary disease. However, two large clinical trials have
peciﬁcally tested whether a statin is of beneﬁt to patients
ith heart failure, and both yielded disappointing results. In
he Controlled Rosuvastatin Multinational Trial in Heart Fail-
re (CORONA), 5,011 patients aged 60 years or older, with
ystolic heart failure were randomized to placebo or to rosu-
astatin 10mg/day and were followed for a median of 32.8
onths [27]. The primary outcome (a composite of cardio-
ascular death, myocardial infarction, and stroke) was not
igniﬁcantly reduced in the rosuvastatin group (hazard ratio
.92, 95% conﬁdence interval 0.83—1.02, p = 0.12). Fewer
ospitalizations for worsening heart failure were seen in the
osuvastatin group (1,109 versus 1,299, p = 0.01); however,
he number of patients with hospitalization for heart failure
as not signiﬁcantly reduced.
In a recent post hoc analysis, CORONA patients with a
lasma amino-terminal pro-B-type natriuretic peptide level
n the lower tercile, below 103 pmol/L, had a lower event
ate if assigned to the rosuvastatin group (hazard ratio 0.65,
5% conﬁdence interval 0.47—0.88) [28]. The outcome in
he low tercile group was signiﬁcantly different than in the
ther two terciles (p = 0.019). As expected, plasma levels of
mino-terminal pro-B-type natriuretic peptide were strongly
redictive of adverse outcomes.
Higher C-reactive protein (CRP) levels were also asso-
iated with a worse outcome in CORONA [29]. In a
etrospective analysis, patients with a baseline CRP level
2.0mg/L experienced a reduction in cardiovascular death,
yocardial infarction or stroke, the primary endpoint of the
rial (hazard ratio 0.87, 95% CI 0.77—0.98) [29]. Total mor-
ality was reduced by 11% by rosuvastatin in patients with a
aseline CRP level ≥2.0mg/L (p = 0.05) and was increased
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y 17% in patients with a baseline CRP level < 2.0mg/L
p = 0.14). It is tempting to speculate that rosuvastatin might
roduce beneﬁt in heart failure patients with high CRP levels
ue to its anti-inﬂammatory activity.
In the Gruppo Italiano per lo Studio della Soprav-
ivenza nell’Insufﬁcienza cardiaca (GISSI) Heart Failure
rial, 4,574 patients with chronic heart failure irrespective
f cause were randomly assigned to rosuvastatin 10mg/day
r placebo and followed for a median of 3.9 years [30]. In this
rial rosuvastatin had no effect upon the co-primary end-
oints, either total mortality or death and hospitalization
or a cardiovascular cause.
What conclusions can we draw from all of these data
egarding the utility of statins in heart failure? First, 5 of the
rials showed that a statin [22,27] or a higher dose of a more
otent statin [23—25] reduced hospitalizations for heart fail-
re. This reduction occurred in studies of patients with
table coronary disease [22,23,27] and after acute coronary
yndromes [24,25], and with 3 different statins: simvastatin
22,25], high-dose atorvastatin [6,23,24], and rosuvastatin
27]. This beneﬁt of statins is important because hospital-
zations for heart failure are frequent and expensive, and
nterfere with the quality of life of coronary patients.
Second, statins appear to reduce cardiovascular events
n patients with mild heart failure. This effect was most
learly seen in the post hoc CORONA analysis, where patients
ith lower natriuretic peptide levels had fewer events with
osuvastatin [28]. In the Heart Protection Study, the abso-
ute beneﬁt of simvastatin was relatively constant across
ifferent natriuretic peptide levels, but the absolute bene-
t was smaller at higher levels [21]. This is consistent with
he notion that patients with severe heart failure are more
ikely to succumb to a fatal arrhythmic event, an endpoint
hat is unaffected by statins.
tatins for the treatment of aortic stenosis
ortic stenosis is the most common acquired valvular disor-
er in developed countries, with a prevalence of 2—4% in
ubjects over age 65 years [31,32]. Aortic stenosis and coro-
ary atherosclerosis share common risk factors, including
ypertension, and hypercholesterolemia [31,33]. In mouse
odels of early aortic stenosis, aortic valve histopatholog-
cal abnormalities are accelerated by elevated cholesterol
evels, and can be stabilized and reversed by cholesterol
owering, including with a statin [34,35].
Statins have been reported to slow the progression of aor-
ic stenosis in non-randomized, retrospective cohort studies,
sing either serial Doppler echocardiography [36—40] or
lectron beam computed tomography [41]. In a prospective,
on-randomized study of 121 asymptomatic patients with
oderate to severe aortic stenosis followed for a mean of
3 weeks, aortic valve area decreased less (p = 0.041) and
ortic valve velocity increased less (p = 0.007) in patients
reated with rosuvastatin 20mg/day compared to controls
42].On the other hand, the Scottish Aortic Stenosis and Lipid
owering Trial, Impact on Regression (SALTIRE) randomized
55 patients to either placebo or atorvastatin 80mg/day and
ollowed them for a mean of 25 months [43]. The primary
ndpoints, change in aortic-jet velocity by Doppler echocar-
t
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iography and change in aortic valve calcium score by helical
omputed tomography, were not signiﬁcantly different in
he two treatment groups.
The largest study to assess the effect of a statin on aortic
tenosis is the Simvastatin and Ezetimibe in Aortic Stenosis
SEAS) Trial [44]. In this study, 1,873 patients with asymp-
omatic, mild-to-moderate aortic stenosis were randomized
o simvastatin 40mg plus ezetimibe 10mg/day or to placebo
nd were followed for a median of 52 months. As shown
n Fig. 1, fewer patients experienced ischemic cardiovascu-
ar events in the simvastatin—ezetimibe group (15.7% versus
0.1%; hazard ratio 0.78, 95% conﬁdence interval 0.63—0.97,
= 0.02). However, aortic valve replacement was performed
n 28.3% of the simvastatin—ezetimibe patients compared
o 29.9% of placebo-treated patients (hazard ratio 1.00,
5% conﬁdence interval 0.84—1.18). No signiﬁcant differ-
nce was seen in peak aortic-jet velocity between the two
reatment groups during the follow-up period, as shown in
ig. 2.
Why did SALTIRE and SEAS fail to conﬁrm the beneﬁt
f statins for aortic stenosis that was suggested by ear-
ier studies? An obvious explanation is that non-randomized,
bservational studies are often misleading due to inherent,
nrecognized bias, and that animal models do not ade-
uately mirror the complexities of human disease. It is also
ossible that a statin might be effective in the early stages
f aortic stenosis, but that by the time a gradient has devel-
ped, the pathologic abnormalities are irreversible, and will
rogress despite treatment [45]. Supporting this concept,
ne observational study found that statins slowed progres-
ion in aortic sclerosis and mild aortic stenosis, but not
n moderate aortic stenosis [46]. Finally, because multiple
echanisms contribute to the progression of aortic steno-
is, it may be unrealistic to expect treatment with only one
gent to be effective.
tatins and Alzheimer’s disease
lzheimer’s disease is a chronic, progressive neurodegen-
rative condition that is a major cause of disability and
nstitutionalization among older persons. Currently avail-
ble treatment for Alzheimer’s disease, cholinesterase
nhibitors and an N-methyl-D-aspartate receptor antagonist,
ave some effect on disease symptoms but do not halt
rogression of the disease [47]. The cause of Alzheimer’s dis-
ase is thought to be the accumulation of -amyloid (A) in
he brain. Cholesterol modulates the processing of amyloid
recursor protein-related A production in animal models
nd in vitro [48]. Excess cholesterol increases the process-
ng of amyloid precursor protein and the production of A,
hereas removing cholesterol slows production of A in
xperimental models [49,50]. Simvastatin has been shown to
ave a similar effect on the processing of amyloid precursor
rotein and the production of A [51].
High cholesterol levels, along with diabetes, smoking,
ypertension, obesity and a sedentary lifestyle, are risk fac-
ors for the development of Alzheimer’s disease in later life
52,53]. Several observational studies indicate that the risk
f developing Alzheimer’s disease is lower in patients taking
tatins [54—57]. In two clinical trials of statins for cardio-
ascular disease prevention in patients at high-risk, (the
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Heart Protection Study and PROSPER), no differences were
detected in cognition tests or new onset dementia between
statin-treated and placebo-treated patients [58].
In patients with mild Alzheimer’s disease, statins were
reported to slow disease progression in a non-randomized,
observational study [59]. In a small randomized clini-
cal trial involving only 67 patients with mild-to-moderate
Alzheimer’s disease, atorvastatin appeared to produce bor-
derline statistically signiﬁcant beneﬁt in some measures of
cognition compared to placebo [60].
The Lipitor’s Effect in Alzheimer’s Dementia (LEADe)
study is the ﬁrst adequately powered, randomized trial to
assess the effect of a statin on the progression of Alzheimer’s
disease [61]. A total of 640 patients with mild-to-moderate
impairment, all receiving donepezil 10mg/day, were ran-
domized in a double-blind manner to atorvastatin 80mg/day
or to placebo. The follow-up period was 72 weeks. The co-
primary endpoints, change in cognition and change in global
function as assessed by standardized tests, declined to a
similar extent in both treatment groups. The high dose of
atorvastatin was well tolerated in this elderly age group,
and no unexpected adverse events were observed.
The Cholesterol Lowering Agent to Slow Progression of
Alzheimer’s Disease (CLASP) Study planned to randomize 400
patients with mild-to-moderate Alzheimer’s disease to sim-
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Figure 1 Outcome events in the Simvastatin and Ezetimibe in Aort
the simvastatin plus ezetimibe and placebo groups were seen for ma
B), or death from any cause (panel D). However, ischemic cardiovasc
group (panel C). See text for details. Reproduced, with permission,159
astatin 20—40mg/day or to placebo and to follow them for
8 months [62]. This trial has been completed and the results
ave been reported as showing no beneﬁt for simvastatin;
owever, the results have not yet been published.
Why do we again ﬁnd a disparity between the positive
esults of observational studies and encouraging data from
nimal models on the one hand, and the negative results
f randomized, placebo-controlled trials on the other? One
ossibility is that statins might be effective in preventing
he onset of the disease, but that once even mild symp-
oms have appeared, the pathological processes may be too
dvanced for statins to exert a beneﬁcial effect. More likely,
ur understanding of the mechanisms causing Alzheimer’s
isease is incomplete, and we are not aiming our therapy at
he optimal target.
tatins for other diseases
tatins stimulate bone formation in experimental models
63] and the majority of observational studies show that
tatin users have fewer fractures [64]. However, randomized
ontrolled trials have demonstrated that neither simvastatin
or atorvastatin improves bone mineral density in post-
enopausal women [65,66].
ic Stenosis (SEAS) Trial [44]. No signiﬁcant differences between
jor cardiovascular events (panel A), aortic valve events (panel
ular events were signiﬁcantly reduced in the active treatment
from Rossebo et al. [44].
160
Figure 2 In the Simvastatin and Ezetimibe in Aortic Steno-
sis (SEAS) Trial, serum low-density lipoprotein (LDL)-cholesterol
(panel A) was reduced by 61% to a mean of 53± 23mg/dL in
the active treatment group. However, peak aortic-jet velocity
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[s measured by Doppler echocardiography (panel B), did not
iffer during follow-up between the groups. Reproduced, with
ermission, from Rossebo et al. [44].
Statins improve survival in animal models of sepsis [67].
recent meta-analysis of 16 cohort studies found that
tatins prevented infection (hazard ratio 0.57, 95% conﬁ-
ence interval 0.43—0.75) and improved outcome among
atients with infection (hazard ratio 0.55, 95% conﬁdence
nterval 0.36—0.83) [68]. Six ongoing randomized controlled
rials are evaluating the efﬁcacy of statins in various types
f infection [69].
Statins have also been assessed in other inﬂammatory
onditions. A double-blind, randomized, placebo-controlled
rial in just 16 patients with rheumatoid arthritis showed
igniﬁcant improvement in inﬂammatory biomarkers and
unctional status in the statin-treated group [70]. In an
ncontrolled study of 41 patients with relapsing-remitting
ultiple sclerosis, statin treatment reduced the number of
adolinium-enhancing lesions, a marker of disease activity
71]. Some (but not all) studies in experimental models sug-
[D.D. Waters
est that statins might be of beneﬁt in lupus erythematosis
72,73]. Whether statins increase or decrease the risk of
eveloping Parkinson’s disease is controversial, with inad-
quate data available to resolve the issue [74]. However,
tatins have been reported to produce improvement in a
ouse model of this disease [75].
In conclusion, statins are effective, established therapy
or the prevention of vascular events in patients at risk.
heir widespread use has resulted in a marked decline in car-
iovascular events in many countries over the past decade.
ttempts to expand the indications of statins, as treatment
or heart failure, aortic stenosis, and Alzheimer’s disease,
ave as yet proved unsuccessful.
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